Tevogen Inc. (TVGN) Stock Price & Analysis

Tevogen Inc. (TVGN) rose 2.37% to USD 7.34 as of September 8, 2026 at 05:02 UTC, according to Nexqual real-time market data.

TVGN last closed at USD 7.34; the session ranged USD 6.94–7.34 on volume of 1,961 shares. Market capitalization is —, with a 52-week range of USD 3.64–46.5 (NGM). Source: Nexqual, September 8, 2026 at 05:02 UTC.

Key Statistics (as of September 8, 2026 at 05:02 UTC)

Technical Analysis (TVGN)

Nexqual's technical model rates TVGN "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 05:02 UTC.

From Tevogen Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• However, we believe our proprietary approach to manufacturing TVGN 489 may allow us to monitor the sequences of emerging variants and, if necessary, to proactively adjust or fine tune our products to ensure that they continue to recognize and treat current and future variants of this and other viruses.
• Although our initial product development has been in the area of infectious disease, we believe our technology also holds promise for applications in cancers and autoimmune diseases, which would increase our total addressable market.
• We also believe that ExacTcell can enable us to deliver products faster, at a greater scale, and at lower cost than future competing cell therapies, if any.       ExacTcell focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, preselected antigenic peptides present only on virus-infected or malignant cells and to kill those cells.
• Contrasted with our approach, the genetically unmodified T cells used after hematopoietic stem cell transplantation for the treatment of viral infections have used large viral proteins, pools of peptides, or infected cells to stimulate CTLs.

Partnerships

• Moreover, TVGN 489 cells are functionally tested after generation, and have been observed to remain strongly cytolytic at very low ratios of CTLs to target cells, which shows that they are not displaying the functional limitations associated with T cell exhaustion.   Manufacturing   We relied on a Clinical Trial Services and Materials Agreement with Thomas Jefferson University for the manufacture of TVGN 489 for our Phase 1 proof-of-concept trial.
• Through our Tevogen.AI artificial intelligence initiative, we are exploring ways to deploy artificial intelligence-powered target detection to accelerate our product development pace, either internally or in collaboration with leading entities in the field of artificial intelligence, such as through our enrollment in the Microsoft for Startups program and use of Microsoft Azure.   As illustrated in the figure below, we begin the ExacTcell process by collecting cells from a healthy donor.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:02 UTC. This page is informational and not investment advice.